Drug Trial Radar · NCT07458269
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
264
Actual
Start
Mar 4, 2026
Primary completion
May 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Conditions
- Obesity
Interventions
RibupatideDrug
SC Injection
PlaceboDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight at Week 48Time frame: Baseline, Week 48
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Kailera Clinical Site
Mesa, Arizona
Kailera Clinical Site
Sun City West, Arizona
Kailera Clinical Site
Irvine, California
Kailera Clinical Site
Lake Forest, California
Kailera Clinical Site
Lomita, California
Kailera Clinical Site
Long Beach, California
Kailera Clinical Site
Montclair, California
Kailera Clinical Site
Rolling Hills Estates, California
Kailera Clinical Site
San Diego, California
Kailera Clinical Site
Santa Ana, California
Kailera Clinical Site
Van Nuys, California
Kailera Clinical Site
DeLand, Florida
Kailera Clinical Site
Orlando, Florida
Kailera Clinical Site
Orlando, Florida
Kailera Clinical Site
The Villages, Florida
Kailera Clinical Site
Decatur, Georgia
Kailera Clinical Site
Woodstock, Georgia
Kailera Clinical Site
Morton, Illinois
Kailera Clinical Site
Indianapolis, Indiana
Kailera Clinical Site
Louisville, Kentucky
Kailera Clinical Site
Rockville, Maryland
Kailera Clinical Site
St Louis, Missouri
Kailera Clinical Site
Lincoln, Nebraska
Kailera Clinical Site
Omaha, Nebraska
Kailera Clinical Site
East Syracuse, New York
Kailera Clinical Site
Greensboro, North Carolina
Kailera Clinical Site
Monroe, North Carolina
Kailera Clinical Site
Raleigh, North Carolina
Kailera Clinical Site
Greenville, South Carolina
Kailera Clinical Site
Myrtle Beach, South Carolina
Kailera Clinical Site
Knoxville, Tennessee
Kailera Clinical Site
Memphis, Tennessee
Kailera Clinical Site
Garland, Texas
Kailera Clinical Site
San Antonio, Texas
Kailera Clinical Site
Winchester, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.